In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
This marks Glenmark's first synthetic decapeptide injectable approval
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Subscribe To Our Newsletter & Stay Updated
